1
|
Blaxill J, Buzzacott P, Finlay J. Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy. Vet Comp Oncol 2021; 20:215-226. [PMID: 34464024 DOI: 10.1111/vco.12768] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 08/26/2021] [Accepted: 08/26/2021] [Indexed: 11/25/2022]
Abstract
Lomustine, vincristine, procarbazine and prednisolone (LOPP) chemotherapy has been suggested to be an effective treatment for dogs with naïve non-indolent T-cell lymphoma (TCL). Studies evaluating prognostic factors for dogs with TCL treated with LOPP chemotherapy are lacking. The aim of this retrospective study was to assess potential prognostic factors for canine naïve non-indolent TCL treated with the LOPP protocol. This was a retrospective cohort study of naïve non-indolent TCL treated with the LOPP chemotherapy protocol at a single specialty veterinary oncology clinic. Sixty-seven dogs met the inclusion criteria. The outcomes assessed included progression free survival (PFS), overall survival time (OST) and duration of complete response (DCR). The overall median PFS was 118 days (range 7-2302 days). The median OST was 202 days (range 8-2302 days). The overall median DCR was 316 days (range 38-2261 days). Number of treatments administered (p < .0001), multicentric disease (p = .044) and the presence of hypercalcaemia (p = .006) were prognostic indicators for PFS. Increasing number of treatments (p < .0001) and age (p = .0088) were prognostic indicators for OST. To our knowledge, this is the first study to describe hypercalcaemia as a positive prognostic indicator of PFS for TCL treated with LOPP chemotherapy. LOPP chemotherapy can be considered as a first-line treatment protocol against naïve hypercalcaemic non-indolent TCL.
Collapse
Affiliation(s)
- John Blaxill
- University of Sydney Veterinary Teaching Hospital, Sydney, New South Wales, Australia
| | - Peter Buzzacott
- School of Nursing, Curtin University, Bentley, Western Australia, Australia
| | - Jessica Finlay
- Perth Veterinary Specialists, Osborne Park, Western Australia, Australia
| |
Collapse
|
2
|
Sayag D, Chamel G, Bédard C, Beauchamp G, Couturier S, Ponce F, Rannou B. Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma. Vet Clin Pathol 2020; 49:476-483. [PMID: 32955128 DOI: 10.1111/vcp.12893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2019] [Revised: 01/03/2020] [Accepted: 01/10/2020] [Indexed: 11/27/2022]
Abstract
Response to chemotherapy is one of the most important prognostic factors in dogs with lymphoma. The objective of this feasibility study was to evaluate if clinical responses to a specific cytotoxic agent (L-asparaginase) could be anticipated by measuring analyte concentrations in plasma and urine concentrations of lymphoma-bearing dogs. We hypothesized that potassium and phosphate concentrations in plasma and urine would be higher in dogs that completely responded to therapy. Plasma and urine samples of dogs with lymphoma were obtained before 12 and 24 hours after intramuscular L-asparaginase injections. Peripheral lymph node volumes were evaluated according to the Veterinary Cooperative Oncology Group standardized criteria. Plasma and urine electrolyte, calcium, phosphate, creatinine, urea, total protein, and albumin concentrations were measured, and the fractional excretions of each electrolyte were calculated. Statistical analyses compared complete vs partial responders using a linear regression model. Contrast analyses were also performed to differentiate the mean of each group, with adjustments made with the Benjamini-Hochberg procedure. Fourteen dogs were included, eight with complete responses, and six with partial responses. Plasma phosphate concentrations were significantly higher at 12 hours (P = .0003) and 24 hours (P = .009) after complete responses to therapy. This study demonstrates the potential use of plasma and urine analyte monitoring after chemotherapy induction. Plasma phosphate measurements represent a potential indicator of early responses to L-asparaginase therapy. Larger population studies are warranted to confirm these preliminary results.
Collapse
Affiliation(s)
- David Sayag
- Oncology Unit, ADVETIA Centre Hospitalier Veterinaire, Velizy Villacoublay, France.,Ecole Nationale Vétérinaire de Toulouse - Centre Hospitalier Universitaire Vétérinaire, Toulouse, France
| | - Gabriel Chamel
- University of Lyon, VetAgro Sup Campus Vétérinaire de Lyon, UR ICE, Service de Cancérologie, Marcy L'Etoile, France
| | - Christian Bédard
- Faculty of Veterinary Medicine, Université de Montreal, Saint-Hyacinthe, QC, Canada
| | - Guy Beauchamp
- Faculty of Veterinary Medicine, Université de Montreal, Saint-Hyacinthe, QC, Canada
| | - Solange Couturier
- Laboratoire de Biologie Médicale, University of Lyon, VetAgro Sup, Marcy l'Etoile, France
| | - Frédérique Ponce
- Ecole Nationale Vétérinaire de Toulouse - Centre Hospitalier Universitaire Vétérinaire, Toulouse, France
| | - Benoit Rannou
- Laboratoire de Biologie Médicale, University of Lyon, VetAgro Sup, Marcy l'Etoile, France.,Azur-Vet Lab - Centre de Vétérinaires Spécialistes AZURVET, Saint Laurent du Var, France
| |
Collapse
|
3
|
Harding K, Bergman N, Smith A, Lindley S, Szivek A, Milner R, Brawner W, Lejeune A. Response rate to a single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma. Vet Comp Oncol 2018; 16:636-641. [PMID: 30117260 DOI: 10.1111/vco.12433] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2018] [Revised: 07/11/2018] [Accepted: 07/12/2018] [Indexed: 12/12/2022]
Abstract
Vincristine is included in vincristine, cyclophosphamide, doxorubicin and prednisone (CHOP) chemotherapy protocols, which are the gold-standard treatment for high-grade canine lymphoma. Vincristine can result in relatively high rates of gastrointestinal toxicity, whereas vinblastine is generally well tolerated and thus may represent an under-utilized and minimally toxic alternative to vincristine. Our objective was to determine the response rate and toxicity associated with a single dose of vinblastine administered to dogs with treatment-naïve, intermediate to large-cell, multicentric lymphoma. Twenty client-owned dogs were enrolled with signed owner consent. A Simon's minimax, phase II, two-stage trial was performed to test the efficacy of vinblastine administered at 2 mg/m2 IV followed by a pilot trial of vinblastine at 2.5 mg/m2 . No dogs were administered concurrent steroids or other chemotherapy. One out of 14 dogs receiving vinblastine at 2 mg/m2 demonstrated a partial response. Three out of five dogs demonstrated a partial response to vinblastine at 2.5 mg/m2 . Gastrointestinal toxicity was infrequent and low grade for both groups. The majority of dogs (80%) in the 2.5 mg/m2 dosing group developed neutropenia 1-week post administration. Vinblastine was well tolerated but minimally efficacious at a dose of 2 mg/m2 IV in dogs with treatment-naive, multicentric lymphoma. Because of poor response rates, treatment at this dose is not recommended. A small subset of dogs administered 2.5 mg/m2 had significantly improved response rates (P = 0.04), suggesting that higher doses may have improved efficacy, although further research is indicated to confirm these preliminary findings.
Collapse
Affiliation(s)
- K Harding
- University of Florida Small Animal Hospital, Gainesville, Florida
| | - N Bergman
- Wilford and Kate Bailey Small Animal Teaching Hospital, Auburn University, Auburn, Alabama
| | - A Smith
- Wilford and Kate Bailey Small Animal Teaching Hospital, Auburn University, Auburn, Alabama
| | - S Lindley
- Wilford and Kate Bailey Small Animal Teaching Hospital, Auburn University, Auburn, Alabama
| | - A Szivek
- University of Florida Small Animal Hospital, Gainesville, Florida
| | - R Milner
- University of Florida Small Animal Hospital, Gainesville, Florida
| | - W Brawner
- Wilford and Kate Bailey Small Animal Teaching Hospital, Auburn University, Auburn, Alabama
| | - A Lejeune
- University of Florida Small Animal Hospital, Gainesville, Florida
| |
Collapse
|
4
|
Tierny D, Serres F, Segaoula Z, Bemelmans I, Bouchaert E, Pétain A, Brel V, Couffin S, Marchal T, Nguyen L, Thuru X, Ferré P, Guilbaud N, Gomes B. Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma. Clin Cancer Res 2015; 21:5314-23. [PMID: 26169968 DOI: 10.1158/1078-0432.ccr-14-3174] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Accepted: 07/04/2015] [Indexed: 11/16/2022]
Abstract
PURPOSE F14512 is a new topoisomerase II inhibitor containing a spermine moiety that facilitates selective uptake by tumor cells and increases topoisomerase II poisoning. F14512 is currently in a phase I/II clinical trial in patients with acute myeloid leukemia. The aim of this study was to investigate F14512 potential in a new clinical indication. Because of the many similarities between human and dog lymphomas, we sought to determine the tolerance, efficacy, pharmacokinetic/pharmacodynamic (PK/PD) relationship of F14512 in this indication, and potential biomarkers that could be translated into human trials. EXPERIMENTAL DESIGN Twenty-three dogs with stage III-IV naturally occurring lymphomas were enrolled in the phase I dose-escalation trial, which consisted of three cycles of F14512 i.v. injections. Endpoints included safety and therapeutic efficacy. Serial blood samples and tumor biopsies were obtained for PK/PD and biomarker studies. RESULTS Five dose levels were evaluated to determine the recommended dose. F14512 was well tolerated, with the expected dose-dependent hematologic toxicity. F14512 induced an early decrease of tumoral lymph node cells, and a high response rate of 91% (21/23) with 10 complete responses, 11 partial responses, 1 stable disease, and 1 progressive disease. Phosphorylation of histone H2AX was studied as a potential PD biomarker of F14512. CONCLUSIONS This trial demonstrated that F14512 can be safely administered to dogs with lymphoma resulting in strong therapeutic efficacy. Additional evaluation of F14512 is needed to compare its efficacy with standards of care in dogs, and to translate biomarker and efficacy findings into clinical trials in humans.
Collapse
Affiliation(s)
- Dominique Tierny
- Oncovet Clinical Research, SIRIC ONCOLille, Avenue Paul Langevin, Villeneuve d'Ascq, France
| | - François Serres
- Oncovet Clinical Research, SIRIC ONCOLille, Avenue Paul Langevin, Villeneuve d'Ascq, France
| | - Zacharie Segaoula
- Oncovet Clinical Research, SIRIC ONCOLille, Avenue Paul Langevin, Villeneuve d'Ascq, France. Inserm, UMR-S1172, Jean Pierre Aubert Research Centre, Lille, France. Université de Lille, Lille, France
| | - Ingrid Bemelmans
- Oncovet Clinical Research, SIRIC ONCOLille, Avenue Paul Langevin, Villeneuve d'Ascq, France
| | - Emmanuel Bouchaert
- Oncovet Clinical Research, SIRIC ONCOLille, Avenue Paul Langevin, Villeneuve d'Ascq, France
| | - Aurélie Pétain
- Institut de Recherche Pierre Fabre, Oncology Pharmacokinetics, Toulouse, France
| | - Viviane Brel
- Institut de Recherche Pierre Fabre, Experimental Oncology Research Center, Toulouse, France
| | - Stéphane Couffin
- Institut de Recherche Pierre Fabre, Pharmacokinetics, Bel Air de Campans, Castres, France
| | - Thierry Marchal
- UPSP 2011-03-101, Interaction Cellules Environnement, Campus Vétérinaire de VetAgro-Sup, Marcy l'Etoile, France
| | - Laurent Nguyen
- Institut de Recherche Pierre Fabre, Oncology Pharmacokinetics, Toulouse, France
| | - Xavier Thuru
- Inserm, UMR-S1172, Jean Pierre Aubert Research Centre, Lille, France. Université de Lille, Lille, France
| | - Pierre Ferré
- Institut de Recherche Pierre Fabre, Oncology Pharmacokinetics, Toulouse, France
| | - Nicolas Guilbaud
- Institut de Recherche Pierre Fabre, Experimental Oncology Research Center, Toulouse, France
| | - Bruno Gomes
- Institut de Recherche Pierre Fabre, Experimental Oncology Research Center, Toulouse, France.
| |
Collapse
|
5
|
Munasinghe LI, Kidney BA, MacDonald-Dickinson V, Larson VS, Jackson ML, Fernandez NJ. Evaluation of lymph node aspirates at diagnosis and relapse in dogs with high-grade multicentric lymphoma and comparison with survival time. Vet Clin Pathol 2015; 44:310-9. [PMID: 25676780 DOI: 10.1111/vcp.12243] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Canine high-grade multicentric lymphoma, a common disease with variable response to chemotherapy, is often diagnosed using cytology. OBJECTIVES The purpose of the study was to compare cytologic features of canine peripheral lymph node aspirates collected at diagnosis and at relapse, and evaluate their usefulness in predicting survival. METHODS Cytologic scoring based on a rubric and nuclear morphometry analyses were performed on cytologic smears collected at diagnosis and at relapse. Scores at diagnosis and relapse were compared by paired t-test and evaluated in relation to time from diagnosis to remission, remission to relapse, relapse to death, and total survival time, using the Cox proportional-hazards regression model. RESULTS Number of mitoses and total cytologic score were significantly higher at relapse compared to diagnosis (P < .05). None of the nuclear morphometry measures were significantly different between diagnosis and relapse. The presence of binucleated or multinucleated cells at diagnosis was associated with a shorter remission and decreased total survival (P < .05). Increased mean nucleoli at relapse was associated with longer remission and total survival (P < .05). Increased minimum nuclear radius and diameter at diagnosis were associated with a decreased time from relapse to death (P < .05). Several nuclear morphometry measures at relapse were associated with a shorter time from diagnosis to remission (P < .05). CONCLUSIONS Number of mitoses and total score were higher at relapse than at diagnosis in canine lymphoma. The presence of binucleated or multinucleated cells at diagnosis may be useful as indicator of a poor prognosis. Further studies including a larger number of cases are required to reinforce the prognostic values of these cytologic features.
Collapse
Affiliation(s)
- Lilani I Munasinghe
- Department of Veterinary Pathology, WCVM, University of Saskatchewan, Saskatoon, SK, Canada
| | - Beverly A Kidney
- Department of Veterinary Pathology, WCVM, University of Saskatchewan, Saskatoon, SK, Canada
| | | | - Victoria S Larson
- Department of Calgary Animal Referral and Emergency Centre, University of Calgary, Calgary, AB, Canada
| | - Marion L Jackson
- Department of Veterinary Pathology, WCVM, University of Saskatchewan, Saskatoon, SK, Canada
| | - Nicole J Fernandez
- Department of Veterinary Clinical and Diagnostic Sciences, Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
6
|
Childress MO, Fulkerson CM, Lahrman SA, Weng HY. Inter- and intra-rater reliability of calliper-based lymph node measurement in dogs with peripheral nodal lymphomas. Vet Comp Oncol 2014; 14 Suppl 1:74-81. [PMID: 25399863 DOI: 10.1111/vco.12125] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Revised: 09/23/2014] [Accepted: 10/01/2014] [Indexed: 11/28/2022]
Affiliation(s)
- M. O. Childress
- Departments of Veterinary Clinical Sciences; College of Veterinary Medicine, Purdue University; West Lafayette IN USA
| | - C. M. Fulkerson
- Departments of Veterinary Clinical Sciences; College of Veterinary Medicine, Purdue University; West Lafayette IN USA
| | - S. A. Lahrman
- Departments of Veterinary Clinical Sciences; College of Veterinary Medicine, Purdue University; West Lafayette IN USA
| | - H.-Y. Weng
- Comparative Pathobiology; College of Veterinary Medicine, Purdue University; West Lafayette IN USA
| |
Collapse
|
7
|
Alexandrakis I, Tuli R, Ractliffe SC, Tappin SW, Foale RD, Roos A, Slater KJ. Utility of a multiple serum biomarker test to monitor remission status and relapse in dogs with lymphoma undergoing treatment with chemotherapy. Vet Comp Oncol 2014; 15:6-17. [PMID: 25319380 DOI: 10.1111/vco.12123] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2013] [Revised: 09/09/2014] [Accepted: 09/16/2014] [Indexed: 12/22/2022]
Abstract
A blinded retrospective study was conducted to investigate remission and recurrence of lymphoma in dogs receiving chemotherapy. The objective was to compare clinicians' assessment using palpation and cytology to the results of serum biochemical tests for haptoglobin (Hapt) and C-reactive protein (C-RP). These biochemical test results were combined using a diagnostic algorithm developed using data from 344 individual dogs. This multivariate approach, termed the canine lymphoma blood test (cLBT), was used to follow 57 dogs during and after treatment. cLBT of remission and recurrence compared well with clinicians' assessment and differentiated dogs in remission and those with recurring disease before appearance of lymphadenopathy (P < 0.001). The cLBT demonstrated prognostic potential based on pre-treatment values on dogs with shorter survival times and on those achieving the lowest cLBT score during treatment that showed longer survival times. The test, therefore, demonstrates potential to assist in monitoring treatment of canine lymphoma.
Collapse
Affiliation(s)
- I Alexandrakis
- Avacta Animal Health Unit 651, Thorp Arch Estate, Wetherby, LS23 7FZ, UK
| | - R Tuli
- Avacta Animal Health Unit 651, Thorp Arch Estate, Wetherby, LS23 7FZ, UK
| | - S C Ractliffe
- Avacta Animal Health Unit 651, Thorp Arch Estate, Wetherby, LS23 7FZ, UK
| | - S W Tappin
- Dick White Referrals Station Farm, Cambridgeshire, CB8 0UH, United Kingdom
| | - R D Foale
- Dick White Referrals Station Farm, Cambridgeshire, CB8 0UH, United Kingdom
| | - A Roos
- Dierenkliniek Korte Akkeren, Gouda, Netherlands
| | - K J Slater
- Avacta Animal Health Unit 651, Thorp Arch Estate, Wetherby, LS23 7FZ, UK
| |
Collapse
|
8
|
Mas A, Blackwood L, Cripps P, Murphy S, De Vos J, Dervisis N, Martano M, Polton GA. Canine tonsillar squamous cell carcinoma - a multi-centre retrospective review of 44 clinical cases. J Small Anim Pract 2011; 52:359-64. [DOI: 10.1111/j.1748-5827.2011.01075.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Abstract
Practical relevance Feline uveitis can be a subtle, insidious, painful, vision-threatening disease with causes that can sometimes be fatal. It is essential that clinicians remain alert to its various clinical presentations, thoroughly diagnose cases once detected, and treat the primary cause whenever possible. Clinical challenges In the majority of patients, a cause is not found and aggressive immunomodulating therapy of what may become a chronic or recurrent immune-mediated disease must be instigated. As with immune-mediated disease elsewhere, this involves local or systemic immunosuppression with slow tapering and frequent monitoring. The aim of this review is to aid diagnosis and therapy of uveitis by likening it to inflammation elsewhere (because it is more similar than it is different) while highlighting differences (because these are helpful). Global importance Feline uveitis is similar in its presentation throughout the world. Although the list of infectious causes may vary in composition or order of likelihood, idopathic, immune-mediated and neoplastic causes of feline uveitis are univerasal. Patient group Patients of either gender and all ages and breeds are affected by uveitis. Evidence base Despite the fact that feline uveitis is a serious and common disorder, the peer-reviewed literature regarding this disease is somewhat limited. Approximately half the publications are review articles, case reports or case series. The majority of prospective and retrospective research describes epidemiologic surveys of antibodies, antigens and organism DNA in serum and aqueous humor.
Collapse
Affiliation(s)
- David J Maggs
- University of California Davis, Davis, CA 95616, USA.
| |
Collapse
|
10
|
Nielsen L, Toft N, Eckersall PD, Mellor DJ, Morris JS. Serum C-Reactive Protein Concentration as an Indicator of Remission Status in Dogs with Multicentric Lymphoma. J Vet Intern Med 2007. [DOI: 10.1111/j.1939-1676.2007.tb01943.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|